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HIV-1 RNA quantitation continues to be extremely important for monitoring patients infected with HIV-1, and a number of
assays have been utilized for this purpose. Differences in assay performance with respect to log10 recovery and HIV-1 subtype
specificity have been well documented for commercially available assays, although comparisons are usually limited to one or two
assay platforms. Two new FDA-approved assays, the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test (RT) and the Abbott
RealTime HIV-1 assay (AR), that utilize real-time PCR have replaced previous HIV-1 RNA platforms. Inadequate detection of
some strains of HIV-1 resulted in the addition of a new primer/probe set and the introduction of a second version of the RT as-
say. In this study, comparisons of assay performance between the different FDA-approved HIV-1 RNA assay platforms (both
new and existing) were performed by using validation data that included both well-characterized virus stock and locally col-
lected clinical samples. Laboratories across diverse geographical regions performed the validation testing and submitted data to
the Virology Quality Assurance program (VQA) for analysis. Correlation values for clinical sample testing varied across the as-
say platforms (r  0.832 to 0.986), and average log10 recoveries for HIV-1 RNA controls (compared to the nominal value) ranged
from 0.215 to 0.181. These data demonstrate the need for use of one assay platform for longitudinal patient monitoring, but
the data also reinforce the notion that no one assay is superior and that testing across platforms may be required for discordance
reconciliation.
HIV-1 RNA quantitation (virus load testing) continues to be animportant tool for monitoring HIV-1 infection (16, 29), and
a number of different commercially available HIV-1 RNA assays
are available for this purpose (1, 9, 10, 12, 20, 21, 26, 27, 28).
HIV-1 RNA results are used to determine antiretroviral treatment
efficacy, monitor safety and adherence, stratify patients enrolled
in clinical trials, and predict virologic outcomes, such as mother-
to-child transmission, treatment failure, and viral persistence in
body compartments. In recent years, there has been a change in
virus load methodologies, from endpoint PCR determinations to
real-time PCR (10, 21, 27). The new real-time PCR methodologies
offer a broad range of benefits over the traditional endpoint PCR,
including higher precision, full automation with high throughput,
expanded reportable range capabilities, and ever-decreasing lower
limits of detection (20 to 40 copies/ml). However, with the im-
proved sensitivity comes concern over an increased frequency of
low-level viremia being detected (8, 18, 24) and the implications
this may have for clinical management.
Four FDA-approved HIV-1 RNA assays (with multiple ver-
sions and platforms) were available in the United States from 2008
to 2011: the Abbott RealTime HIV-1 assay (AR); the Roche Cobas
AmpliPrep/Cobas TaqMan HIV-1 test, versions 1 and 2 (RTv1
and RTv2); the Roche Amplicor HIV-1 Monitor test, version 1.5
(standard [STD] and ultrasensitive [US], the Cobas AmpliPrep
[CAM], Cobas [COB], and microwell plate [MON] versions); and
the Versant HIV-1 RNA 3.0 (bDNA) assay. An understanding of
how the results generated from the different HIV-1 RNA assays
compare is critical for all HIV-1 subtypes, especially since the ge-
netic diversity of HIV-1 continues to evolve and underquantita-
tion of HIV-1 continues to be documented (4, 11, 13, 23). Surveil-
lance and comparative studies worldwide (2, 17, 22, 25, 30, 31) are
extremely important for documenting potential problems and
forcing manufacturers to improve their assays in response to de-
ficiencies (6, 7, 14). The high cost associated with the full automa-
tion of new real-time PCR assays has forced manufacturers to
offer manual versions of the assays, but the impact of using man-
ual extraction methods on precision across laboratories is not fully
understood (5, 19). Many factors contribute to the variability of
HIV-1 RNA measurements, including both systematic and bio-
logical variables (3). Parameters of assay performance that must
be understood include accuracy, precision, sensitivity, specificity,
and reproducibility across laboratories. More recent studies have
shown good correlation among the current versions of the real-
time PCR assays (6, 14, 29); the results of these studies demon-
strate how comparative testing has forced assay improvement.
The Virology Quality Assurance program (VQA) is funded by
the U.S. National Institutes of Health (NIH), National Institute of
Allergy and Infectious Diseases (NIAID), Division of AIDS
(DAIDS), to provide quality control, quality assurance, and qual-
ity assessment (proficiency testing) to laboratories performing
HIV-1 virologic testing for NIH-sponsored clinical trials (32). The
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VQA developed an HIV-1 RNA assay validation plan that was
utilized by client laboratories to validate newly installed FDA-
approved HIV-1 RNA assays. Data from these validation studies
were combined to summarize the overall performance of the new
real-time PCR assays (RTv1, RTv2, and AR) with the previous
endpoint PCR assays (STDCAM, USCAM, STDCOB, USCOB,
STDMON, and USMON). This evaluation is novel because it
combines the testing of a well-characterized control stock across
multiple assay platforms with the testing of locally collected clin-
ical samples from laboratories representing diverse geographical
regions.
(The VQA validation plan was presented, in part, as a poster at
the 15th Conference on Retroviruses and Opportunistic Infec-
tions, Montreal, CA, February 2009, poster 1001.)
MATERIALS AND METHODS
The validation plan required each laboratory to run VQA HIV-1 RNA
copy controls with known nominal values, which were based on the dilu-
tion of a well-characterized stock virus (32) into commercially available
pooled human plasma (sodium citrate treated) or pooled human serum to
which a liquid EDTA solution (500 mM; Sigma) was added (final concen-
tration, 6 mM). The controls used in the validation testing were first
produced in human plasma (citrate) and then in serum plus 6 mM EDTA
to accommodate any assay (specifically, RTv2) that requires the use of
EDTA plasma for sample collection. Titration experiments conducted by
the VQA demonstrated that the log10 recoveries in samples produced with
serum containing 6 mM EDTA were similar to those noted in samples
created using EDTA-treated plasma (data not shown). Plasma was de-
rived from locally obtained donor samples collected in EDTA Vacutain-
ers. VQA controls were combined with clinical samples according to pre-
defined templates that were tested over five separate days. Each template
was tested using the new and existing comparator assays. All assays were
performed according to the package insert for each assay that was used.
Only valid data were included in these analyses. Sample validity was de-
fined by each assay manufacturer and included requirements for kit con-
trol performance to fall within the specified range, internal control per-
formance, and quantitation standard performance. A quantitative result
was required for all samples, except for samples with low copy numbers.
Samples with a titer above the upper limit of detection for the assay were
to be diluted, and HIV-1 RNA values were calculated from retesting of the
diluted sample.
Statistics. Data generated from VQA HIV-1 RNA controls were used
for analyses of accuracy, precision, linearity, and sensitivity, and locally
collected clinical samples were used for analyses of specificity and clinical
sample correlations.
For each control sample, the log10 recovery was computed as the log10-
transformed result minus the log10-transformed nominal value. Linear
mixed effects models were fit to the log10 recovery for each sample from
each assay and control matrix and included precision components for
intrarun, interrun, and interlaboratory variations as well as fixed effects
corresponding to concentration-specific estimates of recovery (CSERs).
Intralaboratory total assay standard deviations (SD) were computed as the
square root of the sum of the intrarun and interrun variance. A critical
threshold of the intralaboratory total assay SD was set at 0.15, which
corresponded to the clinical target of being able to detect a 5-fold change
in virus load with 90% power and a type I error rate of 95%. Overall
accuracy was estimated using a design-weighted average of the CSERs.
The three linearity parameters assessed in the individual validation
plan included the slope and residual standard deviation (SDresid) of a
linear fit to the CSERs as well as the standard errors of the means (SEM) of
CSERs. Acceptance bounds for these linearity parameters were derived
from data simulations and pertained to the maximum variation that
would be expected for an individual validation (34 control samples from
one laboratory across 5 runs) having a total assay SD lower than the target
of 0.15. In individual validations, linearity problems were noted if all three
parameters exceeded their respective acceptance bounds. The mean esti-
mates of the linearity parameters across all laboratories were estimated
from the CSERs derived from the linear mixed effects model used for the
precision analysis (described above). That model also included laboratory-
specific estimates of linear deviations from the CSERs as part of the inter-
laboratory SD component, and these were used to derive estimates of the
interlaboratory SD for the slope and SEM parameters.
Sensitivity evaluations were performed by calculating the percentage
of samples that yielded detectable results for samples with a nominal value
near the limit of detection for each assay. The result needed only to be a
qualitative result, indicating that HIV-1 RNA was detected. Samples with
nominal values of 25 and 50 copies/ml were chosen for these studies, even
though the lower limits of detection for each assay platform do vary. The
main purpose of these analyses was to evaluate performance based on the
respective kit manufacturer claims; the secondary purpose was to evaluate
performance across the control matrices.
The results generated for seropositive clinical samples were compared
across each validated pair of platforms. Discordance was defined as a
result that differed between the two assays with respect to qualitative and
quantitative detection. For the samples that had quantitative results for
both platforms, the correlation was assessed, and the difference between
log10-transformed results for the two assay platforms was computed. Cor-
relations below 0.95 and individual differences that exceeded 5-fold (0.7
log10) were deemed problematic. Bland-Altman plots were constructed,
and a smooth trend along with a 95% confidence band that controlled for
lab-specific variation was fit to the differences across the mean concentra-
tion. In addition, the 90% limits of agreement (LOA) were included on
these plots. The 90% LOA is a measure of the overall degree of agreement
between the two assays and can be interpreted as the range in which we
expect 90% of the differences between the 2 assays to fall. It is calculated as
the average difference across all seropositive samples 1.96 times the
standard deviation of the differences. The expectation is that this interval
will fall within the 0.7 log10 range.
RESULTS
Assays and data sets. The nominal value and number of replicates
of VQA HIV-1 RNA controls and unique clinical donor samples
tested for each validation evaluation were predefined. These in-
cluded replicates of HIV-1 RNA controls with nominal values for
copies/ml (with n indicated in parentheses) of 25 (4), 50 (8), 1,500
(9), 15,000 (9), 150,000 (9), and 1,500,000 (7), as well as locally
collected plasma from 20 unique HIV-1-uninfected and 39 HIV-
1-infected subjects. All samples were tested using the same tem-
plates and were assayed on the new and comparator assay plat-
forms over five consecutive days. The number of validation data
sets received for each assay and control matrix is provided in Table
1. A total of 40 unique data sets were received from 32 laboratories,
representing 15 countries enrolled in the VQA HIV-1 RNA profi-
ciency testing program (Table 2) over 3 years (2008 to 2011).
Thirteen data sets were used to validate the installation of the AR
assay using the automated m2000sp sample processing instru-
ment (ARAUTO); 11 data sets were submitted for the validation
of the AR assay using the manual extraction procedure (ARMAN);
12 data sets were submitted for the validation of the RTv1 assay;
and 7 data sets were submitted for the validation of the RTv2 assay.
Comparator assays varied by laboratory and included a range of
FDA-approved assays. For five data sets, comparator testing was
performed by the VQA or other contracted laboratory by using a
previously validated, FDA-approved assay; all other data sets in-
cluded data generated by one laboratory for both the new and
comparator assay testing.
Accuracy. Accuracy for each assay and control matrix, as esti-
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mated by the average log10 recovery across the four highest nom-
inal concentrations of VQA HIV-1 RNA copy number controls, is
presented in Table 3. A log10 recovery of zero suggested that there
was no difference between the result obtained with a given assay
and the nominal value of the control. A negative log10 recovery
suggested that the assay reported values lower than the nominal
value, and a positive log10 recovery indicated the result was higher
than the nominal value. Average log10 recovery varied across all
assays. Average log10 recovery for citrate controls ranged from
0.124 for USMON to 0.431 for RTv2. Average log10 recovery for
EDTA controls ranged from 0.215 for ARAUTO to 0.181 for
USCAM. In some cases, differences in average log10 recoveries
were noted between platforms of the same assay; for EDTA con-
trols, average log10 recoveries for USMON, USCOB, and USCAM
were 0.119, 0.107, and 0.181, respectively. Differences in average
log10 recoveries were also noted between extraction methods of
the same assay; the average log10 recoveries for EDTA controls
were 0.215 and 0.021 for the ARAUTO and ARMAN, respec-
tively.
Precision. Intralaboratory total SD of log10 recoveries were
higher than the target of 0.15 for the combined data sets generated
using the STDCAM assay for controls produced in citrate and in
the combined data sets generated with USCAM for controls pro-
duced in EDTA (Table 3). The combined data for all platforms of
the STD Roche Amplicor HIV-1 Monitor test in citrate and for all
platforms of the US Roche Amplicor HIV-1 Monitor test in EDTA
showed an elevated intralaboratory total SD. Intrarun variation
was the main cause for this elevated precision statistic regardless of
the matrix. An interlaboratory component of variation was also
evaluated for this analysis. Adding the interlaboratory variation to
the inter- and intrarun variations provided an overall total assay
standard deviation that was estimated for each assay. The overall
total assay standard deviations ranged from 0.083 to 0.266 for
citrated controls and from 0.159 to 0.225 for EDTA-treated con-
trols. A definitive target for this precision parameter has not yet
been established.
Linearity. The linearity parameters (slope, SDresid, and SEM)
are presented in Table 4. All parameters should be close to zero
when there is constant recovery across concentrations. For the
RTv2 assay in citrate, the mean slope and SEM parameters ex-
ceeded the target value; however, it should be noted that the as-
sessment was based upon data from one laboratory with a re-
stricted range of nominal concentrations. For the RTv2 assay in
EDTA, the large negative slope across concentrations indicates a
decreasing linear bias across concentrations. The other linearity
parameters were within range for all platforms, indicating no ev-
TABLE 1 Validation panels tested per assay and control matrix
Assay Abbreviation
No. of validation panels
tested (by control matrix)
Citrate EDTA Total
Abbott RealTime 0.6 ml
(automated extraction)
ARAUTO 10 3 13
Abbott RealTime 0.6 ml
(manual extraction)
ARMAN 3 8 11
Roche TaqMan v1.0 RTv1 9 3 12
Roche TaqMan v2.0 RTv2 1 6 7
Roche standard
Cobas-Ampliprep
STDCAM 5 0 5
Roche standard Cobas STDCOB 2 4 6
Roche standard MWP STDMON 0 5 5
Roche standard (all
platforms combined)
STD 7 9 16
Roche Ultrasensitive
Cobas-Ampliprep
USCAM 3 2 5
Roche Ultrasensitive Cobas USCOB 1 1 2
Roche Ultrasensitive MWP USMON 4 2 6
Roche Ultrasensitive (all
platforms combined)
US 8 5 13
TABLE 2 Participating laboratories
Data





1 Chapel Hill, NC 11/20/08 ARAUTO USMON
2 Chicago, IL 11/20/08 ARAUTO USMON
3 Chicago, IL 11/20/08 ARAUTO USCOB
4 Chicago, IL 09/01/10 RTv2 USCOB
5 Chiang Mai, Thailand 11/20/08 ARAUTO USMON
6 Durban, South Africa 11/20/08 RTv1 STDCAM
7 Lusaka, Zambia 11/20/08 RTv1 STDCAM
8 Lusaka, Zambia 04/20/10 ARAUTO STDCAM
9 Lusaka, Zambia 05/27/10 ARAUTO RTv1
10 Moshi, Tanzania 11/20/08 ARAUTO USCOB*
11 Moshi, Tanzania 11/20/08 ARMAN
12 Durham, NC 11/20/08 RTv1 USMON*
13 Baltimore, MD 04/21/09 ARAUTO USMON
14 Johannesburg, South Africa 08/21/09 RTv1 STDCAM
15 Johannesburg, South Africa 07/05/11 RTv2 RTv1
16 Johannesburg, South Africa 07/05/11 ARAUTO RTv1
17 Kingston, Jamaica 09/23/09 RTv1 USCAM
18 Johannesburg, South Africa 10/16/09 ARAUTO STDCAM
19 Johannesburg, South Africa 10/16/09 RTv1
20 Johannesburg, South Africa 10/16/09 RTv2
21 Bangkok, Thailand 02/19/10 RTv1 USCAM
22 Chiang Mai, Thailand 03/9/10 ARMAN STDCOB
23 Chennai, India 03/15/10 ARMAN STDCOB
24 Khonkaen, Thailand 04/20/10 RTv1 USCAM*
25 Gaborone, Botswana 05/27/10 ARAUTO USCAM
26 Pittsburgh, PA 07/09/10 RTv2 USMON
27 Johannesburg, South Africa 07/28/10 ARAUTO USCAM
28 Eldoret, Kenya 07/28/10 ARMAN STDMON
29 Harare, Zimbabwe 08/24/10 ARMAN STDMON
30 Chicago, IL 09/01/10 RTv2 RTv1*
31 Buenos Aires, Argentina 11/19/10 RTv2 USCAM
32 Nairobi, Kenya 11/19/10 ARMAN STDMON
33 Pune, India 12/06/10 ARMAN STDCOB
34 Entebbe, Uganda 12/06/10 RTv2 STDCOB
35 Port au Prince, Haiti 01/31/11 ARMAN STDCOB
36 Birmingham, AL 01/31/11 RTv2 RTv1
37 Pune, India 03/14/11 ARMAN STDCOB
38 Rio de Janeiro, Brazil 03/14/11 ARMAN USMON*
39 Blantyre, Malawi 04/14/11 ARAUTO STDMON
40 Kampala, Uganda 05/17/11 ARMAN STDMON
a *, in five comparator data sets, comparator testing was performed by the VQA or
other contracted laboratory using a previously validated, FDA-approved assay; all other
data sets included data generated by one laboratory for both the new and comparator
assay testing.
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idence of either linear or nonlinear deviation from a flat trend
across concentrations. Figure 1 provides a depiction of the linear-
ity assessment for all laboratories for each assay and control ma-
trix. Overall linear trends were more similar across assays for
EDTA controls than for citrated controls.
Assay sensitivity. The lower limits of detection were evaluated
across assays using VQA controls with nominal values of 25 and 50
copies/ml (Table 5). Detection was based on the corresponding
manufacturer definition. Briefly, a sample was detected if a mini-
mum optical density (CAM, COB, and MON) or if a minimum
cycle threshold (RTv1, RTv2, and AR) was obtained. The ultra-
sensitive endpoint PCR assays (USCAM, USCOB, and USMON)
have a lower detection limit of 50 copies/ml; the standard end-
point PCR assays (STDCAM, STDCOB, and STDMON) have a
lower detection limit of 400 copies/ml; the real-time PCR assays
have lower detection limits of 20, 40, and 48 copies/ml for RTv2,
AR (MAN and AUTO), and RTv1, respectively. Detection rates
for the standard endpoint PCR assays were very low (0 to 31%) for
both control concentrations, regardless of matrix, but these con-
trols had nominal values that were well below the lower detection
limit of the assays.
Excluding the standard endpoint PCR assays, a total of 96 to
100% of the citrated control samples with nominal values of 50
copies/ml were detected, compared to only 63 to 100% of the
EDTA controls. The ARAUTO, RTv1, and USCAM assays de-
tected 71, 83, and 63% of EDTA controls with a nominal value of
50 copies/ml, respectively; these were all significantly lower than
would be expected based on a 95% detection rate at 50 copies/ml
(P  0.001, P  0.03, and P  0.001, respectively). Samples with a
nominal value of 25 copies/ml were detected in 81 to 100% and 38
to 100% of the citrated and EDTA controls, respectively (Table 5).
For the endpoint PCR assays, one false-positive result each was
noted for the USCAM assay (63 copies/ml) and for the USMON
assay (detected, 50 copies/ml) on specimens that were con-
firmed negative by HIV-1 antibody testing performed by the test-
ing laboratory, using an FDA-approved assay. No other false-pos-
itive results were noted with any other assay platform. Carryover
effects, e.g., from running a sample with no HIV-1 RNA immedi-
ately following a sample with a very high virus load, were assessed
by running several negative samples immediately following sam-
ples with a nominal value of 1,500,000 copies/ml. No carryover
effect was noted in any of the HIV-1 RNA assays (data not shown).
Clinical correlations. Table 6 summarizes the comparisons
from the seropositive clinical sample testing. The percentage of
discordant results between the new and comparator assays ranged
from 1 to 10%, 1 to 8%, 2 to 5%, and 1 to 9% for ARAUTO,
ARMAN, RTv1, and RTv2, respectively, for samples near the
lower limits of detection for the assays. There were four results












ARAUTO 0.046 0.059 0.052 0.078 0.061 0.099
ARMAN 0.012 0.042 0.054 0.069 0.045 0.083
RTv1 0.309 0.111 0.016 0.112 0.059 0.127
RTv2 0.431 0.065 0.041 0.076 — —
STDCAM 0.090 0.172 0.022 0.173 0.026 0.175
STDCOB 0.044 0.131 0.000 0.131 0.067 0.147
STDMONd
STDc 0.078 0.161 0.024 0.163 0.038 0.168
USCAM 0.263 0.115 0.056 0.127 0.168 0.211
USCOB 0.011 0.093 0.076 0.120 — —
USMON 0.124 0.146 0.026 0.148 0.133 0.200
USc 0.037 0.132 0.052 0.142 0.225 0.266
EDTA
ARAUTO 0.215 0.051 0.036 0.062 0.184 0.194
ARMAN 0.021 0.067 0.066 0.094 0.130 0.160
RTv1 0.040 0.078 0.043 0.089 0.207 0.225
RTv2 0.133 0.072 0.045 0.085 0.134 0.159
STDCAMd
STDCOB 0.075 0.121 0.013 0.122 0.165 0.205
STDMON 0.081 0.111 0.056 0.124 0.141 0.188
STDc 0.080 0.115 0.047 0.124 0.139 0.187
USCAM 0.181 0.140 0.071 0.157 0.041 0.162
USCOB 0.107 0.087 0.098 0.131 — —
USMON 0.119 0.141 0.000 0.141 — —
USc 0.056 0.136 0.066 0.151 0.151 0.214
a Boldface values indicate when the target threshold was exceeded. —, statistics could not be computed because data were received from only one laboratory for this assay.
b Each laboratory was included in the precision component model, but the interlaboratory precision component was not included in the calculation of the total assay standard
deviation.
c Data sets STD and US represent the combined standard or ultrasensitive data across all platforms for Roche Amplicor HIV-1 Monitor testing, respectively.
d Data were not received for STDMON in citrate or for STDCAM in EDTA.
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where the virus load in a sample was missed (qualitatively detected
or not detected) with one assay and the virus load reported with
the other assay was more than 0.7 log10 RNA copies/ml (5-fold)
higher than the lower detection limit for that assay. In one exam-
ple, the result for a sample that was reported as 550 copies/ml with
the USCAM assay yielded a result of 40 copies/ml HIV-1 RNA
detected with the ARAUTO assay. In two other comparisons, the
ARAUTO assay reported 321 and 160 copies/ml for samples that
were undetectable or qualitatively detected (50 copies/ml) with
the USMON assay. In the fourth example, a result of 1,870 cop-
ies/ml was reported with RTv2 and a result of 400 copies/ml
HIV-1 RNA detected was reported with STDCAM. None of the
other qualitatively discordant results deviated by more than 0.7
log10 copies/ml from the expectation of the assay’s respective
lower detection limit. A total of 413, 366, 261, and 278 clinical
sample pairs that yielded quantitative results for both assays were
tested on ARAUTO, ARMAN, RTv1, and RTv2, respectively.
From those totals, 29 (7%), 11 (3%), 13 (5%), and 7 (3%) of the
samples yielded results that differed by more than 0.7 log10 RNA
copies/ml between the two assays.
The new and comparator assays showed a range of correlation
values across all comparisons made (Fig. 2). All assay comparisons
that included versions of the standard Roche Amplicor HIV-1
Monitor assay (STDCAM, STDCOB, and STDMON) or the ultra-
sensitive Roche Amplicor HIV-1 Monitor assay (USCAM,
USCOB, and USMON) as a comparator were each, respectively,
combined into one graph, because most clinicians do not differ-
entiate between the different extraction methods of these assays.
Correlation values (r) ranged from 0.832 to 0.949 for comparisons
involving ARAUTO, from 0.909 to 0.950 for comparisons submit-
ted for ARMAN, from 0.882 to 0.962 for comparisons performed
against RTv1, and from 0.921 to 0.986 for comparisons involving
RTv2. All of these correlation values were highly significant (P 
0.0001). Bland-Altman plots for the different assay combinations
are shown in Fig. 3. Individual differences that exceeded 0.7 log10






Mean SD Mean SD
Citrate
ARAUTO 0.014 0.019 0.025 0.019 0.025
ARMAN 0.002 0.016 0.016 0.003 0.020
RTv1 0.027 0.018 0.051 0.035 0.023
RTv2 0.096 0.035 0.030 0.124 0.045
STDCAM 0.028 0.042 0.073 0.036 0.055
STDCOB 0.014 0.041 0.048 0.017 0.053
STDMONb
STD 0.039 0.037 0.018 0.051 0.048
USCAM 0.036 0.016 0.049 0.046 0.020
USCOB 0.031 0.032 0.065 0.040 0.041
USMON 0.020 0.032 0.010 0.025 0.041
US 0.014 0.019 0.025 0.019 0.025
EDTA
ARAUTO 0.024 0.014 0.024 0.031 0.017
ARMAN 0.011 0.037 0.016 0.014 0.048
RTv1 0.008 0.023 0.035 0.011 0.030
RTv2 0.065 0.015 0.062 0.083 0.019
STDCAMb
STDCOB 0.009 0.045 0.062 0.012 0.058
STDMON 0.005 0.035 0.073 0.007 0.045
STD 0.032 0.056 0.020 0.042 0.073
USCAM 0.010 0.056 0.046 0.013 0.072
USCOB 0.015 0.054 0.034 0.020 0.069
USMON 0.014 0.042 0.021 0.018 0.054
US 0.024 0.014 0.024 0.031 0.017
a The targets used for the individual validations were 0.056 for the absolute value of the
slope, 0.096 for SDresid, and 0.091 for SEM. Boldface values indicate when the target
threshold was exceeded by the mean estimate for the indicated parameter.
b Data were not received for STDMON in citrate or for STDCAM in EDTA.
FIG 1 Linearity assessment summary by kit. CSERs were derived from the models described in Table 4. The model allows for a nonlinear trend across
concentration that is common to all labs for a given kit (thick black lines). Individual labs may have linear deviations from that overall nonlinear trend (gray
lines). A horizontal reference line is displayed at zero.
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RNA copies/ml were deemed problematic. For two of the compar-
isons (STD versus RTv2 and US versus RTv2), the average differ-
ence between paired results trended significantly away from zero
for a portion of the average concentration range. The 90% limits
of agreement exceeded the 0.7 log10 limit for four of the com-
parisons (STD versus ARAUTO, US versus ARMAN, STD versus
RTv1, and STD versus RTv2), indicating a lack of evidence that the
two platforms are equivalent for these comparisons.
DISCUSSION
Validation testing must be done whenever a new test is intro-
duced, in order to verify the assay specifications set forth by the
manufacturer. A good assay validation plan must include the use
of a well-characterized control material for purposes of verifying
assay specifications as well as use of locally collected clinical sam-
ples for purposes of clinical correlation studies. A number of in-
vestigators have reported significantly discordant virus load re-
sults in samples containing non-B HIV-1 subtypes across the new
HIV-1 RNA real-time PCR assays (4, 11, 13, 23, 26, 31). Such
correlation studies are extremely important and actually resulted
in the modification from the RTv1 to the RTv2 assay (6, 7, 12). For
correlation studies, samples must be tested using the new assay
platform, and those results must be confirmed against a previously
validated assay. This is important from a clinical perspective to
confirm if rebaselining of patient results will be necessary. For this
analysis, validation data were combined to provide novel infor-
mation on HIV RNA assay performance across a variety of assays,
including multiple platforms within a given assay. Despite the
facts that the number of validation data sets varied between new
and comparator assay platforms and there was no confirmation of
the HIV subtype in the clinical sample subsets, these data provide
a rich database generated by a diverse group of testing laborato-
ries. Historically, HIV-1 RNA assays did not mandate the use of
EDTA as a specimen anticoagulant; however, the RTv1 and RTv2
assays now require the use of EDTA for specimen collection. Pre-
liminary analyses based on proficiency testing data suggest that
the log10 recovery of data generated on the RTv1 assay is signifi-
cantly higher than that noted in other assays; this increased log10
recovery was later attributed to the use of citrated plasma for panel
productions. The data generated for validation confirmed this ob-
servation (Table 3). In general, the average log10 recovery was
higher in citrated controls than in EDTA controls across all real-
time PCR assays. One hypothesis is that EDTA is carried through
the extraction and chelates the manganese in the PCR master mix,
changing the efficiency of the PCR. The problem appears to be
greater in assays that utilize magnetic iron-containing particles for
extraction. Iron has a strong affinity for EDTA, so it may help to
carry the EDTA through the extraction, which can affect PCR
efficiency. Both the AR and RT assays utilize extraction reagents
that contain iron (AR uses iron oxide and RT uses magnetic glass
particles). The magnitude of the effect on log10 recovery varies
across the platforms and supports the notion that sample dilu-
tions must be made using diluents that contain EDTA. However,
the effect on accuracy noted in VQA controls produced in citrated
plasma did not translate to clinical samples derived from citrated
whole blood collected in a Vacutainer, which were diluted (15%)
by the liquid anticoagulant (acid citrate dextrose or cell prepara-
tion tube anticoagulant; Becton, Dickinson). The dilution appar-
ently negated the anticoagulant effect (data not shown).
Many components contribute to the variability noted in a real-
time virus load measurement, including biological variability, sys-
tematic variability, and assay variability (3). When monitoring
patients infected with HIV-1 over time, it is important to under-
stand the magnitude of the components of variation and to know
what change in virus load is clinically relevant. Results obtained on
two different HIV-1 RNA platforms may disagree due to differ-
ences in technologies and varying degrees of genetic variability of
HIV-1, which cause problems with primer and probe hybridiza-
tion in these molecular-based HIV-1 RNA assays (6, 7, 23, 30). In
previously published guidance documents, changes in HIV-1
RNA of 0.5 log10 HIV-1 RNA copies/ml (3-fold) were not con-
sidered clinically relevant (29). This criterion was based on the
assumption that the two measurements were generated with the
same assay. In the evaluation described here and in our routine
validation testing, we consider differences of 0.7 log10 HIV-1
RNA copies/ml (5-fold) to be clinically relevant differences. The
larger value was applied because it contains the added variation
component associated with using two different assay platforms for




Results for samples with nominal concn of:
P valueb












ARAUTO 40 90 80 100 1.00
ARMAN 12 92 24 96 0.71
RTv1 36 92 72 96 0.70
RTv2 4 100 8 100 1.00
STDCAM 20 25 40 28 0.001
STDCOB 8 0 16 13 0.001
STDMONc
STD 28 18 56 23 0.001
USCAM 12 83 24 96 0.71
USCOB 4 100 8 100 1.00
USMON 16 81 32 97 0.81
US 32 84 64 97 0.84
EDTA
ARAUTO 12 67 24 71 0.001
ARMAN 32 88 64 100 1.00
RTv1 12 67 24 83 0.03
RTv2 24 88 48 98 0.91
STDCAMc
STDCOB 16 31 32 31 0.001
STDMON 20 0 32 20 0.001
STD 36 14 72 25 0.001
USCAM 8 38 16 63 0.001
USCOB 4 100 8 100 1.00
USMON 4 100 8 100 1.00
US 16 69 32 81 0.01
a The validation controls used for this testing were designed to evaluate assays with
ultralow detection limits (50 copies/ml or less). Standard Roche assays (STDMON)
have lower detection limits of 400 copies/ml. A blank indicates no data were received
for this assay.
b A P value is provided for each assay to indicate if the detection rate of the sample with
a nominal value near the lower detection limit of the assay (e.g., 50 copies/ml) was
significantly different (too many false negatives) than what would be expected by
chance alone for a 95% detection rate.
c Data were not received for STDMON in citrate or for STDCAM in EDTA.
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generating a virus load. For clinical trial testing, many laboratories
from diverse geographical locations contribute data, and inter-
laboratory variation is yet another component of variation that
must be taken into consideration. In this evaluation, the new real-
time PCR assays offered better intralaboratory precision than did
the endpoint PCR assays. When the interlaboratory component
was added to the precision statistic for real-time PCR assays, total
assay precision was increased for all assays, but a target for this
precision statistic is yet to be defined. Higher interlaboratory dif-
ferences were noted in controls produced in EDTA, but this may
have been due to differences in sample sizes. The additional vari-
ation noted between laboratories could be attributed to kit lot
variability, equipment variability, or inexperience with perform-
ing testing. Real-time monitoring of assay performance through
the use of external quality control materials and interlaboratory
performance tracking through external proficiency testing pro-
grams are very important to help monitor this variation.
The linearity analyses presented in this evaluation provide a
novel, quantifiable measure for the assessment of assay linearity.
There are three distinct concepts of linearity that are routinely
assessed in assay validation: the linearity of a diluted sample, per-
formance (accuracy and precision) within a linear range, and con-
stant recovery across a range of concentrations. The first concept
is not clinically relevant in HIV-1 RNA testing, especially now that
real-time PCR assays have such large linear ranges (20 to
10,000,000 copies/ml). The second concept is already addressed
with the assessments of precision and accuracy of well-character-
ized controls that span the linear range of the assays. The third


















ARAUTO RTv1 7 (9) 2 (3) 1 (1) 2 (3) 66 (85) 1 (2)
ARAUTO STDCAM 11 (14) 8 (10) 5 (6) 6 (8) 48 (62) 4 (8)
ARAUTO STDMON 39 (100) 9 (23)
ARAUTO STD 11 (9) 8 (7) 5 (4) 6 (5) 87 (74) 13 (15)
ARAUTO USCAM 1 (1) 2 (3) 75 (96) 7 (9)
ARAUTO USCOB 2 (3) 2 (3) 2 (3) 2 (3) 70 (90) 2 (3)
ARAUTO USMON 15 (10) 12 (8) 3 (2) 6 (4) 5 (3) 115 (74) 6 (5)
ARAUTO US 18 (6) 14 (4) 3 (1) 10 (3) 7 (2) 260 (83) 15 (6)
Total for ARAUTO
comparisons
36 (7) 24 (5) 8 (2) 17 (3) 9 (2) 413 (81) 29 (7)
ARMAN STDCOB 9 (5) 2 (1) 7 (4) 165 (90) 7 (4)
ARMAN STDMON 8 (5) 2 (1) 12 (8) 2 (1) 136 (85) 2 (1)
ARMAN STD 17 (5) 4 (1) 12 (3) 9 (3) 301 (88) 9 (3)
ARMAN USCOB 1 (3) 1 (3) 1 (3) 1 (3) 35 (90) 1 (3)
ARMAN USMON 5 (13) 1 (3) 2 (5) 30 (79) 1 (3)
ARMAN US 6 (8) 2 (3) 2 (3) 1 (1) 1 (1) 65 (84) 2 (3)
Total for ARMAN
comparisons
23 (5) 6 (1) 14 (3) 10 (2) 1 (0.2) 366 (87) 11 (3)
RTv1 STDCAM 16 (10) 3 (2) 7 (4) 7 (4) 123 (79) 11 (9)
RTv1 STD 16 (10) 3 (2) 7 (4) 7 (4) 123 (79) 11 (9)
RTv1 USCAM 1 (1) 2 (2) 1 (1) 113 (97) 1 (1)
RTv1 USMON 10 (26) 2 (5) 1 (3) 1 (3) 25 (64) 1 (4)
RTv1 US 11 (7) 4 (3) 1 (1) 2 (1) 138 (88) 2 (1)
Total for RTv1
comparisons
27 (9) 7 (2) 7 (2) 8 (3) 2 (1) 261 (84) 13 (5)
RTv2 RTv1 3 (3) 7 (6) 1 (1) 106 (91) 1 (1)
RTv2 STDCAM 7 (18) 8 (21) 2 (5) 22 (56) 3 (14)
RTv2 STDCOB 6 (15) 2 (5) 31 (79) 1 (3)
RTv2 STD 13 (17) 2 (3) 8 (10) 2 (3) 53 (68) 4 (8)
RTv2 USCAM 39 (100) 2 (5)
RTv2 USCOB 1 (3) 2 (5) 36 (92) 0 (0)
RTv2 USMON 59 (42) 13 (9) 20 (14) 2 (1) 1 (1) 44 (32) 0 (0)
RTv2 US 59 (27) 14 (6) 20 (9) 4 (2) 1 (0) 119 (55) 2 (2)
Total for RTv2
comparisons
72 (17) 19 (5) 28 (7) 13 (3) 2 (0.5) 278 (67) 7 (3)
a TND, target not detected; Qual, qualitative; Quant, quantitative.
b Results in these categories represent discordant results for samples with low virus titers.
c The results in this category reflect discordance in samples that yielded quantitative results on both the new and comparator virus load assay for which the log10 recovery rate
difference was 0.7. The log10-transformed results from the comparator assay were subtracted from the log10-transformed results obtained with the new assay. Blank cells in the
table indicate that there were no clinical sample pairs that fit the category description.
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concept, constant recovery, was assessed in this evaluation by in-
cluding the slope, SDresid, and SEM parameters presented in Table
4; the RTv2 assay demonstrated an elevated parameter for slope
and SEM in citrate and an elevated slope parameter in EDTA.
The RTv1 assay tended to run slightly lower at the low end of
the linear range, giving it a positive slope from low to high con-
centrations; the RTv2 assay demonstrated a negative slope with
higher recovery at the low end. This may be a consequence of
trying to improve the lower detection limit for this assay. The
ARAUTO and ARMAN assays tended to have constant recoveries
across the linear range, but there was more variability in linearity
parameters between laboratories with the ARMAN assay, as de-
picted by the intersecting lines in the linearity plots. The implica-
tion is that variability in assay calibration may be due to variability
FIG 2 Clinical sample regression plots. Correlations are shown between the comparator assay (y axis) and the new assay (x axis) for each pair of the comparisons.
Multiple labs are represented within each panel, and the correlations were computed after adjusting for within-lab deviations.
FIG 3 Bland-Altman plots. Within each panel, the difference between measurements for each sample (y axis) was computed as the value from the new assay
minus that for the old assay. Horizontal dotted reference lines at 0.7 targets flag individual differences that exceeded 5-fold. The scale was truncated at 1.5 to
allow greater resolution of the trend, and three measurements having values outside that range are displayed using double concentric circles (for US ARAUTO,
the actual value is 2.257; for US ARMAN, the actual value is 2.385; for RTv1 STD, the actual value is 2.823). Nonlinear trends (thick solid lines) were fit to the
data within each panel, along with an interval within which trend lines for 90% of the labs were expected to lie (thick dashed lines). Intervals which exceeded 0.7
for some portion of the concentration range indicate that the average trend for 5% of the labs may exceed 5-fold for those concentrations. Intervals that exclude
zero for some portion of the concentration range indicate that the average trend differed significantly (  0.10) from zero, but perhaps the trend was not
clinically relevant. A 90% LOA (based upon the mean difference  the intralaboratory SD for each comparison) is provided at the top of each panel.
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associated with the manual extraction. Since assay performance
characteristics with respect to accuracy, precision, and linearity
are all interrelated, major failures in assay performance are typi-
cally associated with failures across multiple criteria. Therefore,
elevations in any one parameter, such as the slope or SEM, will
most likely have little effect on clinical management, especially if
other criteria, such as assay precision, fall well below expected
targets. While there were a couple of laboratories that manifested
multiple problems in their validation testing, most problems were
fixed with retraining and retesting, suggesting the problems were
associated with technical performance, not necessarily assay per-
formance. Since EDTA-anticoagulated Vacutainer tubes are typi-
cally used for collection of whole blood for HIV-1 viral loads, the
data generated using EDTA controls are more relevant to log10
recovery data for the assays. The data in this analysis showed av-
erage log10 recoveries of 0.215, 0.021, 0.040, and 0.133 for the
ARAUTO, ARMAN, RTv1, and RTv2 assays, respectively (Table
3). This is consistent with the findings reported by van Rensburg et
al., who showed that the AR assay underreported the WHO stan-
dard by 0.2 to 0.3 log10 RNA copies/ml and the RTv2 assay over-
reported the WHO standard by 0.17 to 0.31 log10 RNA copies/ml
(30). This further demonstrates the importance of using one assay
platform for monitoring longitudinal data for a given subject, as
well as the importance of performing assay validations to deter-
mine the impact of switching virus load platforms.
The broader reportable ranges associated with the real-time
PCR assays may translate to fewer repeat tests and lower costs for
samples with higher virus loads. The newer assays offer better
sensitivity: RTv2 offers a lower detection limit of 20 copies/ml,
compared to 40, 48, or 50 copies/ml for ARAUTO (and ARMAN),
RTv1, or USCOB (USMON or USCAM), respectively. These
lower detection limits may translate to more detectable results.
Viral blips are described as transient detections of virus loads that
are typically below 200 copies/ml and return to undetectable levels
without any change in therapy (15). Increased qualitatively and
quantitatively detected results have been noted in laboratories that
have switched from the USCAM to the RTv1 assay (11, 24) or
RTv2 assay (8). These increases did not translate to increases in
mother-to-child transmission (MTCT) rates, nor did they predict
virologic failure; however, there is concern that increased occur-
rences of detectable viremia could result in unnecessary patient
anxiety or regimen changes. Further problems could occur with
clinical trials where eligibility or treatment failure may be defined
based on viral detection. Since differences do exist between the
HIV-1 RNA assays, it will be important that guidelines and clinical
trial descriptions be updated to reflect these differences. Assay
sensitivity across the new real-time PCR assays was evaluated us-
ing controls with nominal values of 25 and 50 copies/ml. Better
detection rates were noted in citrated controls than in EDTA con-
trols for both the 25-copies/ml (90 to 92% versus 67 to 88%) and
50-copies/ml (96 to 100% versus 71 to 100%) controls for all
real-time PCR assays. A significantly reduced detection rate was
noted in ARAUTO for the 50-copies/ml EDTA controls, but this
was a small data set and would require additional testing to con-
firm these observations. The specificities of the real-time PCR as-
says included in this study were very good, with no true false-
positive results reported. No evidence of carryover contamination
was noted with any of the PCR methodologies, either endpoint or
real-time PCR. This was probably a reflection of the routine qual-
ity control measures against cross-contamination in place at the
laboratories participating in this study.
Laboratories were asked to collect samples from subjects with a
range of virus loads and to limit the number of samples with
undetectable virus loads to 20%, in order to permit adequate
sample sizes. Some laboratories had to test a large number of HIV-
infected samples in order to obtain sufficient numbers of samples
with detectable virus loads. Since the lower detection limits of
assays differ, the presence or absence of low-level viremia in pa-
tient populations can affect concordance rates. Correlation values
did vary, ranging from 0.832 to 0.986, but since there was no
standardization of the number of samples tested at each virus load
across the linear range of the assays, it would not be fair to over-
evaluate these data. Low correlations may artifactually result from
having an inadequate spread of data across the range of virus
loads. The Bland-Altman plots of the same data showed some
systematic trends that were more evident in the linearity plots. The
target for the 90% limit of agreement was set at 0.7 log10 RNA
copies/ml. There were comparisons across assay platforms for
which the 90% LOA exceeded this target (ARAUTO versus STD,
ARMAN versus US, RTv1 versus STD, and RTv2 versus STD). For
purposes of validation, laboratories were instructed to evaluate
instances where discordance in correlation testing exceeded 0.5
log10 RNA copies/ml. In some cases, the discordance was due to
sample mishandling or misreporting of data. Retesting of samples
was not always possible, due to sample volume issues, but no ma-
jor underquantitation was verified as being due to a primer or
probe mismatch or an ongoing problem with clinical populations
in any of the validation data sets.
In summary, as reported in other studies, differences in log10
recoveries do exist across the assay platforms, but good overall
correlations have been noted between endpoint PCR assays and
the RTv2 or AR assays (2, 5, 25, 30). Some deficiencies were pre-
viously observed with the RTv1 assay but appeared to be mostly
resolved with the RTv2 assay (6, 7, 11). However, due to the rapid
evolution of HIV-1 in response to selective pressures and the in-
cidence of newly identified recombinant viruses, ongoing surveil-
lance of HIV-1 RNA assay performance will be critical. Question-
able results should be retested on a different HIV-1 RNA platform
to help resolve potential discordance (4). With respect to low virus
titers, donor screening and eligibility testing performed across dif-
ferent platforms may prove challenging, because the lower limits
of detection vary across assays. Low titers of HIV-1 RNA may be
reported as undetectable by one assay, detectable but less than the
cutoff by a second assay, and reported as a quantitative value by a
third assay with a lower limit of detection. If detection is used as an
eligibility criterion for protocol enrollment, exclusion or inclu-
sion might be biased, depending on the assay used to measure
virus load. If laboratories do not routinely report qualitatively
detected results, then intermittent low-level viral titers may be
misrepresented as virologic failure or misinterpreted as mishan-
dled results. Similarly, if virologic endpoints are placed near or at
the limits of detection of different assay platforms, variability in
clinical outcomes of trials could be affected by the assay used for
virus load testing. Additional studies need to be done to evaluate
the effect of using low-copy-number virologic endpoints on clin-
ical outcomes in relation to the assay used for measuring virus
load. An understanding of the impact of assay performance is
critical, since virus loads are used for clinical management. Assess-
ing performance and determining how certain specifications, such
HIV-1 RNA Cross-Platform Evaluation
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as accuracy, precision, and lower limits of detection, will impact
your results are important for making the right decisions in de-
signing clinical trials and changing treatments.
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